Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?

被引：22
|
作者：
Alsoud, Dahham [1 ]
Vermeire, Severine [1 ,2 ]
Verstockt, Bram [1 ,2 ]
机构：
[1] Katholieke Univ Leuven, Dept Chron Dis Metab & Ageing, Translat Res Gastrointestinal Disorders TARGID IB, Leuven, Belgium
[2] Katholieke Univ Leuven, Dept Gastroenterol & Hepatol, Univ Hosp Leuven, Leuven, Belgium
来源：
CURRENT OPINION IN PHARMACOLOGY | 2020年 / 55卷
关键词：
CROHNS-DISEASE; MAINTENANCE THERAPY; ULCERATIVE-COLITIS; INDUCTION THERAPY; TROUGH LEVELS; SUBCUTANEOUS USTEKINUMAB; CLINICAL PHARMACOKINETICS; DOSE INTENSIFICATION; IBD PATIENTS; INFLIXIMAB;
D O I：
10.1016/j.coph.2020.09.002
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Therapeutic drug monitoring (TDM) plays a vital role in implementing precision medicine in inflammatory bowel disease (IBD), and may contribute to increased effectiveness, lower rates of drug toxicity and cost savings. While expert panels advocate the use of reactive TDM for anti-tumor necrosis factor (anti-TNF) agents, TDM is not yet widely recommended for non-anti TNF biologicals. We provide an overview of the observational evidence of the value of TDM in case of vedolizumab and ustekinumab. We also shed light on obstacles that need to be addressed before establishing wide acceptance of TDM in the field of IBD. In this respect, new analytical techniques and modelling approaches are being developed to further optimize efficacy of TDM and to facilitate general acceptance of this tool in personalizing IBD management.
引用
收藏
页码：17 / 30
页数：14
相关论文
共 50 条
  • [21] REAL WORLD EXPERIENCE IN THERAPEUTIC DRUG MONITORING IN INFLAMMATORY BOWEL DISEASE PATIENTS ON USTEKINUMAB
    Glassner, Kerri
    Irani, Malcolm
    Malaty, Hoda
    Abraham, Bincy P.
    [J]. INFLAMMATORY BOWEL DISEASES, 2019, 25 : S25 - S26
  • [22] VEDOLIZUMAB DRUG LEVELS ARE NOT ASSOCIATED WITH OUTCOMES OR DISEASE ACTIVITY IN INFLAMMATORY BOWEL DISEASE
    Shields, Stephanie
    Seenan, John Paul
    Nowell, Emma
    Dunlop, Allan
    Galloway, Peter
    Macdonald, Jonathan
    [J]. GUT, 2021, 70 : A122 - A123
  • [23] Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study
    Wils, Pauline
    Seksik, Philippe
    Stefanescu, Carmen
    Nancey, Stephane
    Allez, Matthieu
    de Chambrun, Guillaume Pineton
    Altwegg, Romain
    Gilletta, Cyrielle
    Vuitton, Lucine
    Viennot, Stephanie
    Serrero, Melanie
    Fumery, Mathurin
    Savoye, Guillaume
    Collins, Michael
    Goutorbe, Felix
    Brixi, Hedia
    Bouguen, Guillaume
    Tavernier, Noemie
    Boualit, Medina
    Amiot, Aurelien
    Abitbol, Vered
    Laharie, David
    Pariente, Benjamin
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 53 (04) : 460 - 470
  • [24] Proactive Therapeutic Drug Monitoring of Ustekinumab Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease
    Porth, Rachel
    Deyhim, Tina
    Geeganage, Grace
    Smith, Brenden
    Zullow, Samantha
    Rabinowitz, Loren G.
    Grossberg, Laurie B.
    Cheifetz, Adam S.
    Papamichael, Konstantinos
    [J]. INFLAMMATORY BOWEL DISEASES, 2024,
  • [25] OUTCOMES OF DOSE ESCALATION AND DRUG LEVEL MONITORING IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH VEDOLIZUMAB
    Scoville, Elizabeth A.
    Izmaylov, Michelle L.
    Bennett, Audrey
    Evers, Lauren
    Annis, Kim
    Garrett, Ailish
    Duley, Caroline
    Adams, Dawn W.
    Dalal, Robin L.
    Beaulieu, Dawn
    Schwartz, David A.
    Horst, Sara N.
    [J]. GASTROENTEROLOGY, 2018, 154 (06) : S829 - S830
  • [26] Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease
    Barre, A.
    Colombel, J. -F.
    Ungaro, R.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (07) : 896 - 905
  • [27] Comparative Safety of Ustekinumab and Vedolizumab in Older Patients with Inflammatory Bowel Disease: A Bicentric Cohort Study
    Burgevin, Alice
    Caron, Benedicte
    Sasson, Alexa
    Luc, Amandine
    Netter, Patrick
    Baumann, Cedric
    Ananthakrishnan, Ashwin N.
    Peyrin-Biroulet, Laurent
    [J]. JOURNAL OF CLINICAL MEDICINE, 2022, 11 (23)
  • [28] SURGICAL OUTCOMES OF PATIENTS TREATED WITH USTEKINUMAB VS. VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE.
    Novello, M.
    Holubar, S.
    Shawki, S.
    Lipman, J.
    Gorgun, E.
    Hull, T.
    Steele, S. R.
    [J]. DISEASES OF THE COLON & RECTUM, 2018, 61 (05) : E132 - E133
  • [29] COSTS OF DOSE ESCALATION AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH VEDOLIZUMAB AND USTEKINUMAB IN PORTUGAL
    Lopes da Cruz, J. P.
    Faria, M.
    Aleixo, A. S.
    Pereira, F.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S504 - S505
  • [30] Monitoring ustekinumab levels in Inflammatory Bowel Disease in clinical practice: a window of opportunity
    Gonzalez Antuna, J.
    Valdes Delgado, T.
    Maldonado Perez, B.
    Castro Laria, L.
    Merino Bohorquez, V.
    Calleja Hernandez, M. A.
    Arguelles Arias, F.
    [J]. JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1299 - I1300
12345